Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867096-25-000108
Filing Date
2025-06-04
Accepted
2025-06-04 19:01:31
Documents
1
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1749078084.html 4  
1 FORM 4 wk-form4_1749078084.xml 4 3479
  Complete submission text file 0001867096-25-000108.txt   4979
Mailing Address DENDREON CORPORATION 1301 2ND AVENUE SEATTLE WA 98101
Business Address
JOHNSON JOHN (Reporting) CIK: 0001410781 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 251024575

Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

EIN.: 871082097 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)